<code id='8AD359C391'></code><style id='8AD359C391'></style>
    • <acronym id='8AD359C391'></acronym>
      <center id='8AD359C391'><center id='8AD359C391'><tfoot id='8AD359C391'></tfoot></center><abbr id='8AD359C391'><dir id='8AD359C391'><tfoot id='8AD359C391'></tfoot><noframes id='8AD359C391'>

    • <optgroup id='8AD359C391'><strike id='8AD359C391'><sup id='8AD359C391'></sup></strike><code id='8AD359C391'></code></optgroup>
        1. <b id='8AD359C391'><label id='8AD359C391'><select id='8AD359C391'><dt id='8AD359C391'><span id='8AD359C391'></span></dt></select></label></b><u id='8AD359C391'></u>
          <i id='8AD359C391'><strike id='8AD359C391'><tt id='8AD359C391'><pre id='8AD359C391'></pre></tt></strike></i>

          knowledge

          knowledge

          author:focus    Page View:12
          King Street Properties’ Pathway Devens campus. -- biotech coverage from STAT
          Pat Greenhouse/Globe Staff

          MORRISVILLE, N.C. — Ten minutes from the Raleigh airport, the future of biotech is under construction.

          On either side of a new stretch of four-lane highway sit two $1 billion biomanufacturing campuses, which will bring a combined 2.5 million square feet of research and development and advanced manufacturing space to a region that has become the No. 1 place where North America makes prescription drugs.

          advertisement

          One campus, called Pathway Triangle, is being built by a developer from Boston, King Street Properties. King Street — which has projects in Cambridge, Waltham, Allston, and Lexington — is building a similarly vast biomanufacturing campus in Devens. But these days it also sees a land of opportunity 700 miles to the south, in North Carolina.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Eli Lilly to pay $200M for Beam’s stake in gene
          Eli Lilly to pay $200M for Beam’s stake in gene

          AdobeEliLillysaidTuesdaythatitwillpay$200milliontogene-editingfirmBeamTherapeuticsforBeam’sstakeinVe

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Testing for cancer recurrence creates a new limbo for patients

          EssayauthorMaraBuchbinderandherhusband,Jesse(right).CourtesyMaraBuchbinderMyhusband’scancercamebackt